Trice Medical

Why Trice Medical?

Trice Medical was founded to fundamentally improve orthopedic diagnostics. Trice has pioneered fully integrated camera-enabled technologies that provide a clinical solution that is optimized for the physicians’ office. Trice Medical’s FDA-approved 510(k)-cleared device, mi-eye 2, is a handheld 2.2mm arthroscope, consisting of a needle with an integrated camera and a light source designed for in-office use. With mi-eye 2, physicians can provide real-time analysis, effect faster treatment, and schedule patients for surgery immediately—resulting in quicker outcomes for patients and a more efficient process for doctors. The Company has expanded its proprietary platform for use in the neurosurgical, OB-Gyn, ENT and veterinary spaces.

Market Opportunity

In the U.S., it is estimated that more than 8M orthopedic-focused MRI exams are conducted each year. Private insurers, which cover approximately 80% of all sports medicine injuries, often pay an average of $1.5-2K per MRI— implying an addressable market opportunity for Trice of ~$15B.

(Visited 1,901 times, 1 visits today)

Company Milestones

  • Trice Medical appoints Craig Carra as CFO
  • Trice Medical receives FDA 510(k) clearance for mi-eye 2
  • Trice Medical and Pacific Medicalannounce multi-state distribution agreement
  • Trice Medical Closes $19.3 Million Series C Financing To Address Increased Demand For Mi-Eye